Liprolog Mix50 (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle and fat cells, activating signaling pathways that move glucose‑transport proteins to the cell surface. This accelerates glucose uptake from the bloodstream and suppresses liver glucose production, producing a quick drop in post‑prandial blood sugar.

The dose of Liprolog Mix50 is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s carbohydrate intake, current blood glucose levels, body weight, activity level, and overall insulin sensitivity. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Insulin lispro is classified as a pregnancy category that may be used when the expected benefit justifies the potential risk to the fetus. It is excreted in breast milk in small amounts. Pregnant or nursing individuals should discuss use with their healthcare provider to weigh benefits and risks.

To order Liprolog Mix50, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Liprolog Mix50 (insulin lispro) has a rapid onset of action, typically within 15 minutes, and a shorter duration compared with regular human insulin. Its pharmacokinetic profile is similar to other rapid‑acting analogs such as insulin aspart and insulin glulisine, offering flexible mealtime dosing and reduced post‑prandial glucose excursions.

Unopened vials or cartridges of Liprolog Mix50 should be stored at 2‑8 °C (refrigerated) and protected from light. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, but should never be frozen or shaken.

Liprolog Mix50 is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection should be given shortly before a meal, usually within 15 minutes, to match the rapid onset of action. Patients must rotate injection sites to reduce the risk of lipodystrophy.

The most serious risks include severe hypoglycemia, which can lead to seizures, loss of consciousness, or coma, and allergic reactions ranging from rash to anaphylaxis. Rarely, patients may develop insulin antibodies that diminish therapeutic effect. Prompt medical attention is required if any of these events occur.

Liprolog Mix50 should be avoided in individuals with a known hypersensitivity to insulin lispro or any of the product’s excipients. It is also contraindicated in patients with severe hypoglycemia unawareness or those who cannot reliably monitor blood glucose. Clinical judgment is required for patients with significant renal or hepatic impairment.